Inoperable recurrent @entity5 : results of a prospective trial with radiation therapy and XXXX .

@entity1 @entity137 @entity5 @entity3 @entity10976
PURPOSE: The effect of the sensitizer @entity10976 was prospectively evaluated in recurrent @entity5 . Endpoints of the study were mainly local response rates and survival. METHODS AND MATERIALS: From 1984 to 1990 @entity10976 was given together with radiation therapy to 40 @entity1 with recurrent inoperable @entity5 . Loco-regional relapses in the pelvis were isolated in 24 and associated with distant @entity3 in 16 @entity1 . Special attention was given to the subset of 24 @entity1 with isolated local recurrences. This group was compared with historical controls treated with radiotherapy alone. The dosage of @entity10976 was 150 mg/m2 daily orally starting 5 days before the first irradiation. The drug was then given each radiation day until the end of treatment. The median radiation dose was 60 (40-62) Gy in the evaluable @entity1 . The minimum follow-up was 32 months and the median 72 months. RESULTS: The rates of complete plus partial responses were 57% and 54%, respectively, for recurrent @entity1 without and with distant @entity3 . The 23 evaluable @entity1 with isolated local relapses had a median survival of 24 months (12-94+); all @entity1 surviving at least 1 year. CONCLUSION: The combination of radiotherapy and @entity10976 may lead to better local control and improved median survival compared to our historical controls and literature reports where radiotherapy alone was used. The treatment is easy to administer and is associated with a moderate @entity137 .
